242 related articles for article (PubMed ID: 24552817)
1. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.
Kim M; Chen X; Chin LJ; Paranjape T; Speed WC; Kidd KK; Zhao H; Weidhaas JB; Slack FJ
Cell Cycle; 2014; 13(6):1030-40. PubMed ID: 24552817
[TBL] [Abstract][Full Text] [Related]
2. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
Chin LJ; Ratner E; Leng S; Zhai R; Nallur S; Babar I; Muller RU; Straka E; Su L; Burki EA; Crowell RE; Patel R; Kulkarni T; Homer R; Zelterman D; Kidd KK; Zhu Y; Christiani DC; Belinsky SA; Slack FJ; Weidhaas JB
Cancer Res; 2008 Oct; 68(20):8535-40. PubMed ID: 18922928
[TBL] [Abstract][Full Text] [Related]
3. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
[TBL] [Abstract][Full Text] [Related]
4. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
Pharoah PD; Palmieri RT; Ramus SJ; Gayther SA; Andrulis IL; Anton-Culver H; Antonenkova N; Antoniou AC; Goldgar D; ; Beattie MS; Beckmann MW; Birrer MJ; Bogdanova N; Bolton KL; Brewster W; Brooks-Wilson A; Brown R; Butzow R; Caldes T; Caligo MA; Campbell I; Chang-Claude J; Chen YA; Cook LS; Couch FJ; Cramer DW; Cunningham JM; Despierre E; Doherty JA; Dörk T; Dürst M; Eccles DM; Ekici AB; Easton D; ; Fasching PA; de Fazio A; Fenstermacher DA; Flanagan JM; Fridley BL; Friedman E; Gao B; Sinilnikova O; ; Gentry-Maharaj A; Godwin AK; Goode EL; Goodman MT; Gross J; Hansen TV; Harnett P; Rookus M; ; Heikkinen T; Hein R; Høgdall C; Høgdall E; Iversen ES; Jakubowska A; Johnatty SE; Karlan BY; Kauff ND; Kaye SB; Chenevix-Trench G; ; Kelemen LE; Kiemeney LA; Kjaer SK; Lambrechts D; Lapolla JP; Lázaro C; Le ND; Leminen A; Leunen K; Levine DA; Lu Y; Lundvall L; Macgregor S; Marees T; Massuger LF; McLaughlin JR; Menon U; Montagna M; Moysich KB; Narod SA; Nathanson KL; Nedergaard L; Ness RB; Nevanlinna H; Nickels S; Osorio A; Paul J; Pearce CL; Phelan CM; Pike MC; Radice P; Rossing MA; Schildkraut JM; Sellers TA; Singer CF; Song H; Stram DO; Sutphen R; Lindblom A; ; Terry KL; Tsai YY; van Altena AM; Vergote I; Vierkant RA; Vitonis AF; Walsh C; Wang-Gohrke S; Wappenschmidt B; Wu AH; Ziogas A; Berchuck A; Risch HA;
Clin Cancer Res; 2011 Jun; 17(11):3742-50. PubMed ID: 21385923
[TBL] [Abstract][Full Text] [Related]
5. KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer.
Nelson HH; Christensen BC; Plaza SL; Wiencke JK; Marsit CJ; Kelsey KT
Lung Cancer; 2010 Jul; 69(1):51-3. PubMed ID: 19854534
[TBL] [Abstract][Full Text] [Related]
6. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.
Christensen BC; Moyer BJ; Avissar M; Ouellet LG; Plaza SL; McClean MD; Marsit CJ; Kelsey KT
Carcinogenesis; 2009 Jun; 30(6):1003-7. PubMed ID: 19380522
[TBL] [Abstract][Full Text] [Related]
7. A variant in 3'-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPD.
Hu H; Zhang L; Teng G; Wu Y; Chen Y
Int J Chron Obstruct Pulmon Dis; 2015; 10():1641-9. PubMed ID: 26316738
[TBL] [Abstract][Full Text] [Related]
8. A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer.
Li ZH; Pan XM; Han BW; Guo XM; Zhang Z; Jia J; Gao LB
Tumour Biol; 2013 Oct; 34(5):3159-63. PubMed ID: 23729275
[TBL] [Abstract][Full Text] [Related]
9. Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells.
Nakano H; Yamada Y; Miyazawa T; Yoshida T
Int J Oncol; 2013 Jun; 42(6):1875-82. PubMed ID: 23588298
[TBL] [Abstract][Full Text] [Related]
10. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.
Kundu ST; Nallur S; Paranjape T; Boeke M; Weidhaas JB; Slack FJ
Cell Cycle; 2012 Jan; 11(2):361-6. PubMed ID: 22189714
[TBL] [Abstract][Full Text] [Related]
11. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.
Crowley EH; Arena S; Lamba S; Di Nicolantonio F; Bardelli A
Hum Mutat; 2014 Feb; 35(2):208-14. PubMed ID: 24282149
[TBL] [Abstract][Full Text] [Related]
12. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB
Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325
[TBL] [Abstract][Full Text] [Related]
13. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
[TBL] [Abstract][Full Text] [Related]
14. Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer.
Jin H; Liang Y; Wang X; Zhu J; Sun R; Chen P; Nie X; Gao L; Zhang L
Med Oncol; 2014 Oct; 31(10):221. PubMed ID: 25201577
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.
Nodin B; Zendehrokh N; Sundström M; Jirström K
Diagn Pathol; 2013 Jun; 8():106. PubMed ID: 23800114
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.
Hollestelle A; Pelletier C; Hooning M; Crepin E; Schutte M; Look M; Collee JM; Nieuwlaat A; Dorssers LC; Seynaeve C; Aulchenko YS; Martens JW; van den Ouweland AM; Weidhaas JB
Breast Cancer Res Treat; 2011 Jul; 128(1):79-84. PubMed ID: 20676756
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
18. Lack of association between let-7 binding site polymorphism rs712 and risk of nasopharyngeal carcinoma.
Pan XM; Jia J; Guo XM; Li ZH; Zhang Z; Qin HJ; Xu GH; Gao LB
Fam Cancer; 2014 Mar; 13(1):93-7. PubMed ID: 23996697
[TBL] [Abstract][Full Text] [Related]
19. A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer.
De Ruyck K; Duprez F; Ferdinande L; Mbah C; Rios-Velazquez E; Hoebers F; Praet M; Deron P; Bonte K; Speel EJ; Libbrecht L; De Neve W; Lambin P; Thierens H
Cancer Epidemiol; 2014 Oct; 38(5):591-8. PubMed ID: 25127693
[TBL] [Abstract][Full Text] [Related]
20. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.
Paranjape T; Heneghan H; Lindner R; Keane FK; Hoffman A; Hollestelle A; Dorairaj J; Geyda K; Pelletier C; Nallur S; Martens JW; Hooning MJ; Kerin M; Zelterman D; Zhu Y; Tuck D; Harris L; Miller N; Slack F; Weidhaas J
Lancet Oncol; 2011 Apr; 12(4):377-86. PubMed ID: 21435948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
